FDA
-
-
-
-
-
-
-
CSL and uniQure Win 2023 Prix Galien USA Award
-
-
-
-
-
-
-
CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B
-
-
-
-
-
-
-
First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission
-
-
-
-
-
-
-
uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event
-
-
-
-
-
-
-
RBC Capital on uniQure BV (QURE): 'Brain Safety Signal Unfortunate, But Stock Reaction Overdone'
-
-
-
-
-
-
-
Akari Therapeutcis (AKTX) Appoints Rachelle Jacques as President and CEO
-
-
-
-
-
-
-
FDA Removes uniQure BV (QURE) Clinical Hold, Truist Securities Reiterates Buy
-
251,403 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All